💨 Abstract

A study comparing Eli Lilly's Zepbound (tirzepatide) and Novo Nordisk's Wegovy (semaglutide) found that Zepbound users lost nearly 50% more weight (50 pounds vs. 33 pounds) over 72 weeks. Both drugs mimic gut and brain hormones to regulate appetite but Zepbound targets two hormones, while Wegovy targets one. Over 75% of participants experienced mild to moderate side effects.

Courtesy: wtop.com

Summarized by Einstein Beta 🤖